Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters









Database
Main subject
Language
Publication year range
1.
Drug updates and approvals: 2019 in review.
Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; Arcara, Ashley; Yang, Sebin; Brown, Jenna; Mospan, Geoffrey; Mospan, Cortney.
Nurse Pract ; 44(12): 21-32, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31658218

ABSTRACT

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent).


Subject(s)
Drug Approval , Antibodies, Monoclonal/therapeutic use , Azetidines/therapeutic use , Benzyl Compounds/therapeutic use , Carbamates/therapeutic use , Clobetasol/analogs & derivatives , Clobetasol/therapeutic use , Drug Combinations , Formoterol Fumarate/therapeutic use , Heterocyclic Compounds, 3-Ring/therapeutic use , Humans , Lamivudine/therapeutic use , Nicotinic Acids/therapeutic use , Oxazines , Phenylalanine/analogs & derivatives , Phenylalanine/therapeutic use , Piperazines , Pregnanolone/therapeutic use , Pyridones , Tropanes/therapeutic use , United States , United States Food and Drug Administration , beta-Cyclodextrins/therapeutic use
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL